{"Clinical Trial ID": "NCT00248170", "Intervention": ["INTERVENTION 1:", "- Letrozole", "2.5 mg orally (p.s.) once daily", "INTERVENTION 2:", "Anastrozole", "1 mg once daily"], "Eligibility": ["Incorporation criteria:", "Recent primary breast cancer surgery", "Early breast cancer", "Postmenopausal menopausal", "Positive hormone receptor", "Positive lymphatic impairment", "- Exclusion criteria:", "Metastatic diseases", "There is contralateral breast cancer, including CDIS", "Progression", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "\u2022 Disease-free survival", "Disease-free survival was defined as the time between the date of randomization and the date of the first literature on the reoccurrence of invasive breast cancer at local, regional or remote sites, of new invasive breast cancer in the counter-lateral breast, or of death from any cause.", "Time limit: 84 months", "Results 1:", "Title of the arm/group: Letrozole", "Description of the arm/group: 2.5 mg per mouth (p.o.) once daily", "Total number of participants analysed: 2061", "Median (95% confidence interval)", "Unit of measurement: Month NA [1] (84.14 to NA)", "Results 2:", "Title of the arm/group: Anastrozole", "Description of the arm/group: 1 mg per day", "Total number of participants analysed: 2075", "Median (95% confidence interval)", "Unit of measurement: Month NA [1] (NA to NA)"], "Adverse Events": ["Undesirable Events 1:", "Total: 486/2049 (23.72%)", "Anemia 4/2049 (0.20%)", "- Autoimmune haemolytic anaemia 0/2049 (0.00 %)", "Haemorrhagic anaemia 1/2049 (0.05%)", "- Lymphadenopathy 0/2049 (0.00 %)", "Pancytopenia 0/2049 (0.00 %)", "Acute coronary syndrome 1/2049 (0.05%)", "- Acute myocardial infarction 3/2049 (0.15%)", "- Adams-Stokes syndrome 1/2049 (0.05%)", "Angina pectoris 8/2049 (0.39%)", "Unstable Angina 1/2049 (0.05%)", "Adverse Events 2:", "Total: 520/2062 (25.22 per cent)", "Anemia 3/2062 (0.15%)", "1/2062 (0.05%)", "Haemorrhagic anaemia 0/2062 (0.00 %)", "- Lymphadenopathy 2/2062 (0.10%)", "Pancytopenia 1/2062 (0.05%)", "Acute coronary syndrome 1/2062 (0.05%)", "Acute myocardial infarction 4/2062 (0.19%)", "- Adams-Stokes syndrome 0/2062 (0.00 %)", "Angina pectoris 8/2062 (0.39%)", "Unstable Angina 2/2062 (0.10%)"]}